Quarterly Post-Grant and Patent Litigation Update -

Welcome to our ongoing updates relating to biologics and biosimilars, including post-grant and patent litigation challenges to blockbuster biologics. We hope you find this 3Q 2019 update informative. It has been an eventful quarter with 25 biosimilars now approved in the United States and several new IPRs challenging Soliris and Neulasta. As always, please feel free to reach out to us with any questions.